Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
30 8월 2023 - 5:30AM
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that
management will be participating in the following upcoming investor
conferences during the month of September:
- Morgan Stanley
21st Annual Global Healthcare Conference at the Sheraton New York
Times Square Hotel in New York. Marianne De Backer, M.Sc., Ph.D.,
MBA, Chief Executive Officer, is scheduled to participate in a
fireside chat on Tuesday, September 12, at 5:10 a.m. PT / 8:10 a.m.
ET.
- H.C. Wainwright
25th Annual Global Investment Conference at Lotte New York Palace
in New York. Vir management will be hosting 1-on-1 investor
meetings on September 13.
A live webcast of the fireside chat can be
accessed under Events & Presentations in the Investors section
of the Vir website at www.vir.bio and will be archived
there for 30 days.
About Vir BiotechnologyVir
Biotechnology, Inc. is an immunology company focused on combining
cutting-edge technologies to treat and prevent infectious diseases
and other serious conditions. Vir has assembled two technology
platforms that are designed to stimulate and enhance the immune
system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis B and hepatitis delta
viruses, influenza A and B, human immunodeficiency virus and
COVID-19. Vir has several preclinical candidates in its pipeline,
including RSV/MPV and HPV. Vir routinely posts information that may
be important to investors on its website.
Contacts:
Carly Scaduto
Senior Director, Media Relations
cscaduto@vir.bio
+1-314-368-5189
Investors
Sasha Damouni Ellis
Executive Vice President, Chief Corporate Affairs Officer
sdamouni@vir.bio
Vir Biotechnology (NASDAQ:VIR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Vir Biotechnology (NASDAQ:VIR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024